Psychiatry

News

J&J's Spravato gets another lift with new FDA approval

Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.

News

Boehringer drug for brain fog in schizophrenia fails trial

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

Patients

hands holding paper head representing protecting the mind

Keeping stigma out of it: Personalising the mental health co...

Thursday 10th October was World Mental Health Day, focused this year on ‘mental health at work’.

News

Talkiatry co-founders Dr Georgia Gaveras (l) and Robert Krayn (r)

Biogen, Talkiatry team up on postpartum depression

Telehealth company Talkiatry has partnered with Biogen to expand its support service for women who develop postpartum depression (PPD) in a move that could help drive uptake of the latter's

News

BMS ends decades-long drought in novel schizophrenia drugs

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal.

R&D

Embracing diversity many people linked together

Embracing diversity in psychiatry and neurology clinical tri...

There is broad recognition of the need to promote diversity and inclusion in clinical trials, with the goal of improving health equity and enhancing the validity and generalisability of stu

J&J's Spravato gets another lift with new FDA approval

Boehringer drug for brain fog in schizophrenia fails trial

Keeping stigma out of it: Personalising the mental health co...

Biogen, Talkiatry team up on postpartum depression

BMS ends decades-long drought in novel schizophrenia drugs

Embracing diversity in psychiatry and neurology clinical tri...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Psychiatry

Editor's Picks